BDBM305253 US10144734, Example 269::US10172845, Example 269::US10441581, Example 269::US11648243, Example 269

SMILES CCc1ccc(OC2CCN(CC2)c2ccc(cn2)-c2cc(OCC(C)(C)O)cn3ncc(C#N)c23)nc1

InChI Key InChIKey=YOQMWXZKMGHTRZ-UHFFFAOYSA-N

Data  8 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 305253   

LigandPNGBDBM305253(US10144734, Example 269 | US10172845, Example 269 ...)
Affinity DataIC50: 18.8nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/30/2019
Entry Details
US Patent

LigandPNGBDBM305253(US10144734, Example 269 | US10172845, Example 269 ...)
Affinity DataIC50: 18.8nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305253(US10144734, Example 269 | US10172845, Example 269 ...)
Affinity DataIC50: 18.8nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
US Patent

LigandPNGBDBM305253(US10144734, Example 269 | US10172845, Example 269 ...)
Affinity DataIC50: 18.8nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2023
Entry Details
US Patent

LigandPNGBDBM305253(US10144734, Example 269 | US10172845, Example 269 ...)
Affinity DataIC50: 70.2nMAssay Description:The potency of a compound inhibiting G810R mutant RET kinase was determined using CisBio's HTRF Kinease-TK assay technology. The assays contained...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

LigandPNGBDBM305253(US10144734, Example 269 | US10172845, Example 269 ...)
Affinity DataIC50: 70.2nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/30/2019
Entry Details
US Patent

LigandPNGBDBM305253(US10144734, Example 269 | US10172845, Example 269 ...)
Affinity DataIC50: 70.2nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2023
Entry Details
US Patent

LigandPNGBDBM305253(US10144734, Example 269 | US10172845, Example 269 ...)
Affinity DataIC50: 70.2nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
US Patent